Novare Pharmaceuticals is a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of the Receptor for Hyaluronan Mediated Motility, or RHAMM.
RHAMM is a protein that is normally localized inside the cell but is released by certain stimuli. It plays a role in the regulation of spontaneous cell movement and stem cell differentiation. The modulation of RHAMM can provide a safe and efficacious means to selectively promote subcutaneous fat generation (adipogenesis), moderate destructive inflammation, and reduce scarring (fibrosis) by stimulating normal cell differentiation and controlling the body’s own natural regenerative processes.
Novare is developing a dermal filler for aesthetic applications that works via the modulation of RHAMM. This research is being led by Dr. Eva Turley, an oncology scientist at the London Health Sciences Centre (LHSC) in London, Ontario, in collaboration with MJ Bissell, a world-renowned cell biologist at Lawrence Berkeley National Laboratories in Berkeley, California.
Turley and her colleagues have also uncovered the potential for additional applications of RHAMM modulation that may help solve some of today’s biggest medical challenges, including arthritis, fibrotic diseases such as Bronchopulmonary Dysplasia (BPD) in premature infants and Idiopathic Pulmonary Fibrosis (IPF), and the reduction and possible elimination of keloid scars.
This breakthrough in tissue engineering may also provide an opportunity to regenerate and reconstruct women’s breasts after a mastectomy through the localized stimulation of the body’s own adipocyte (fat) stem cells.
More information about Novare and its research can be found on the company’s website: